Connor, Clark & Lunn Investment Management (CC&L)
IMRX icon

Connor, Clark & Lunn Investment Management (CC&L)’s Immuneering IMRX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.11M Buy
400,363
+267,683
+202% +$1.37M ﹤0.01% 946
2025
Q4 		$873K Buy
+132,680
New +$852K ﹤0.01% 1181

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s IMRX Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Immuneering (IMRX) stake by 202% in Q1 2026, buying an estimated $1.37M and bringing the position to 400,363 shares worth $2.11M. The position accounts for ﹤0.01% of the portfolio, ranked #946.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in IMRX in Q4 2025 and has held it in 2 quarters since. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 400,363 shares of Immuneering worth $2.11M as of Q1 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 267,683 Immuneering shares in Q1 2026, an estimated $1.37M.
  • Immuneering made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #946 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Immuneering in Q4 2025 and has held it in 2 quarters since.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.